Autopsy report · NCT04049617
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
Cause of deathFunding or business
“Gilead decision to terminate”
Life of this trial
- Ran for about 1 year 7 months before it stopped.
- 18 participants enrolled.
- Results were posted on the registry 1 year 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Gilead Sciences
- Sponsor type
- Industry
- Conditions
- Advanced Solid Tumors
- Interventions
- Evixapodlin
- Participants
- 18
- Sites
- 6
- Countries
- New Zealand, United States
Trials that died the same way
- Dose Optimization Study of Idelalisib in Follicular Lymphoma
“Gilead has made the decision to close the study due to enrollment challenges”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.